of anticoagulants 80°/. of patients showing a moderate to severe grade of cardiogenic shock die within six weeks of the onset. Left at home, often with inadequate nursing care, deprived of constant supervision, and often perforce with makeshift arrangemants for treatment during the first critical twenty-four or forty-eight hours, these patients often face greater risks than those entailed by their immediate transfer to hospital. Again, lozal conditions mu3t influence the decision which the practitioner must make in difficult circuM3tances. The prompt u3e of heparin should be encouaged, even before the patient leaves homn.
The employment of anticoagulants has widened our outlook on the problems of acute myocardial infarction and has revealed our therapeutic shortcomings. There is still much to learn regarding the immediate effects of these drugs and their long-term influence. REFERENCES GILCiHRIsT, A. R. (1952) Brit. med. J., ii, 351. TULLOCH, J. A., and GrLcsnusr, A. R. (1950) Brit. med. J., ii, 965; (l951)Amer.'Heart1J.,w42, 864.
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Anticoagulant Therapy in Coronary Occlusion
By WILLIAM EVANS, M.D., D.Sc.. F.R.C.P. BEFoRE turning to deal directly with anticoagulant teatment in coronary occlusion, there is a need co define conditions that should govern the acceptance by the profession of a particular medicine as orthodox in the treatment of any ailment. That a patient should have faith in medicine is an admirable thing; it helps him to get well. A doctor's faith in a remedy, however, should be founded on premises other than a simple hope that it will do good, and on a reliance gained from a clinical trial scientifically controlled. EVen if we admit the influence of fashion on therapeutics we must never change a form of treatment just because it is fashionable. to change.
It is better for a new remedy to be reoeived with a quiet scepticism than with a boundless enthusiasm, because a wiser judgment on its real and lasting benefit is more likely to follow. There ar many reasons why a new remedy is hailed with undue enthusiasm. Among them are the desperate need to ltleviate or cure some fell disease, the demonstration of a specific effect in the experimental animal, the comp'elling advertise. ment which appears to brook no contradiction, its warm recommendation by a medical colleague, based too often on a limited experience, its acceptance by another country politically in the ascendancy, the truism that it is always the latest song that an audience applauds the most-a sentiment born on the lips of Homerand the deniiands-made by either ipatient or relative. There is evidence that we are losing our sef-relianee and that we yield too easily to the whims and fancies of our times and our patients. One of the main functions of a doctor is to manage his patients, and when the patients manage their doctors, and there are ominous signs that this is taking place, medicine will have surrendered its professed scientifiClequipment for its ancient cloak of quackery. There is more danger in this than most appear to be aware of; thus, we find it recorded that 50% of American physicians using anticoagulants admitted that they did this because they were pressed to do so by their patients. Progressive medicine should provide that every new remedy must be submitted to a Therapeutic Trials Tribunal before it is dispensed to patients or included in the British Pharrnacopceia. Such a body would outline a plan for an investigation to test the therapeutic value of the drug, and allocate the problem to those competent to solve it, and with facilities to carry out the work and at several centres. A model of such an investigation is afforded by the Christie Report on penicillin in the treatment of bacterial endocarditis. Before a new and potent remedy is accepted for general use it should satisfy a Code ofEfficiency and such a code should demand three requirements of each drug: First, that it should produce noticeable improvement in the majority of patients where its trial has been justified. Secondly, that such improvement should never be less, and, in the large majority of patients, should be much greater than that produced by a placebo. Thirdly, that the remedy can be dispensed in[a convenient form and without risk of preducing injurious effects in'the patients.
THE INCIDENCE OF CORONARY THROMBOSIS Obviously the object of the treatment is to, prevent clotting and primariiy to prevent mromoosis within the coronary circulation, so that it is first necessary to examine the incidence of this event as a forerunner of, an associated finding in, or as a sequel to, cardiac infarction. There are a number of observations on this. In eight such investigations ( Table I ) an absence of clotting in the coronary arteries was found in some 20 % to 90 % of cases examined at necropsy with an average of 57 % for the whole series. This means that had anticoagulant therapy been a universal procedure in these cases with cardiac pain it would have been given to prevent clotting which certainly never took place in 1,358 among 2,351 patients. Thus, anticoagulants dispensed with the purpose of preventing coronary thrombosis can do no good in more than one-half of all cases of cardiac infarction, while in each it can do harm. It is a good precept that no patient should be the worse for seeing a doctor; the patients I have just cited might have been the worse for seeing some doctors. Since anticoagulant therapy cannot reduce the mortality rate by lessening the incidence ot coronary thrombosis in more than one-half the cases, does it in fact reduce it in the other half destined to develop thrombosis? It is not difficult to test the curative value of a medicine in a disease which invariably terminates fatally in the absence of a specific remedy as in the case of bacterial endocarditis. In an illness where recovery takes place without any remedial help, the claim ofa particular form of treatment should be rigidly tested lest the credit of spontaneous recovery be erroneously allotted to the therapy that happens to be administered at the time. It is necessary, therefore, in the case of cardiac infarction, not only to compare the effects of an active medicine with a placebo, but also to ensure as far as is possible that special influences are operating to the same degree in both test and control series. Thus, the factors which are known to affect prognosis must be taken into account, and among these are the size of the occluded artery, the place of the-infarct, the state of the adjoining collateral circulation, the'age of the patient, and the presence of heart failure.
MORTALrrY RATE IN CARDIAC INFARCTION
When the mortality rate in cases of car3Tiafarction treated with anticoaguiants7and with more orthodox measures is examined (Table II) it is not clear why such comparison should have led so many to favour anticoagulant therapy for this has been done on insufficient evidence. Thus, we have a most ardent protagonist of this treatment (Wright et al., 1948) claiming for it a mortality rate of 15% against 24% in the control group, and five years later (Wright, 1953) a mortality rate of 7% against 13 %. Since it is impossible to predict in a patient with cardiac pain that the course of the illness is to be a favourable one, surely a different interpretation may be given to these results, namely, that a mortality rate of 15%/ during anticoagulant therapy compared unfavourably with one of 13% in a control goup. Rytand (1951) quotes another instance where a different interpretation might be given to the published results; it concerms a report where a mortality rate of 40% among patients with cardiac infarction compared unfavourably with onle of 16 % when anticoagulant therapy was practised.
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Rytand states that the mortality rate for the combined group was 28% while in patients at the same hospital treated on orthodox lines in previous years the mortality rate was 26%, and he adds that it. would seem that the prognosis in a patient with cardiac infarctionis worse when anticoagulants are given to someone else. Again, the mortality rate found by the ten observers whose individual results are shown in Table II among the 1,499 patients treated with anticoagulants is far less satisfactory than a mortality rate of 19% in my own series of 1,000 consecutive patients with cardiac infarction who received orthodox treatment, in that this last figure takes into account not only the immediate mortality rate following the initial attack, but also the deaths taking place during a period of upwards of ten years. Thus 590 of them had survived two years, 324 had survived four years, 151 six years, 65 eight years and 32 for over ten years (Evans, 1952) . Furthermore, insufficient care has been taken in the selection of comparable cases in reported control groups, and especially in the assessment of circumstances which materially affect prognosis. Foremost among these is the association of heart failure told clinically by the presence of triple heart rhythm and radiologically by the finding of pulmonary congestion. Thus, in 118 patients with cardiac infarction showing triple heart rhythm the mortality rate was 38%, and in88 with pulmonary congestion it was 40 %, compared with the mortality rate of 19% for the whole series.
The presence of heart failure, therefore, more than doubles the mortality rate in cardiac infarction; a preponderance of such patients in the control group would naturally allot a definite advantage to the test group. (1952) . . .. THROMBO-EMBOLIC EPISODES IN CARDIAC INFARCTION Intracardiac thrombosis cannot be told in the absence of embolism while leg vein thrombosis does not always produce noticeable signs in the affected limb. Pulmonary embolism is the best clinical yardstick to measure the frequency of thrombosis in cardiac infarction because it takes note of systemic vein clotting in addition to thrombosis within the right heart. Although some authors have reported a high incidence of embolism in cardiac infarction, 34 % by Bean (1938) and 31 % by Eppinger and Kennedy (1938), other writers have reported an incidence around 15% for pulmonary embolism; thus, we have 19% (Parkinson and Bedford, 1928), 15% (Conner and Holt, 1930) , 14% (Nay and Barnes, 1945), 12% (Hellerstein and Martin, 1947) and 15 % (Short, 1952) . Ochsner and his colleagues (1950) found that an incidence of thrombo-embolism among patients in the Charity Hospital, New Orleans, had increased from less than 100 among 100,000 in the period of 1938-9 to 250 among 100,000 in 1948-9 when both ligature of veins and anticoagulants had been introduced as routine procedures to prevent this complication. Among 4,451 control cases of cardiac infarction that I have collected from the literature where the incidence of thrombo-embolic episodes has been given this event occurred in 580 or 13 %, while among 1,1 15 patients with cardiac infarction treated with anticoagulants 105 or 9% showed the complication (Table III ). The claim that deaths from thrombo-embolism can be reduced to negligible proportions (Gilchrist, 1952) by anticoagulants has not, therefore, been substantiated, and, so far, no detailed observations in patients examined at necropsy have been published in support of the statement that the difference in the mortality rate between the treated and untreated groups has been due to an increased incidence of thrombo-embolism in the untreated group (Schnur, 1953) . Indeed, recently Kerwin (1953) claimed a decrease in the death-rate in patients with heart failure following cardiac infarction from 60% in the control group to 30% in the one treated with anticoagulants. The incidence of thrombo-embolic episodes in the same series was 12% and 5 % for the respective groups. Seeing that the reduction in the death-rate was clearly not on account of a diminution in the incidence of thrombo-embolism, is this to be acclaimed as indicating the superiority of anticoagulants over digitalis in the treatment of heart failure?
As the clinical diagnosis of thrombosis is notably difficult, embolism may also go unnoticed. The .mistake of nominating the presence of thrombo-embolism when it is not there is matched by the error of missing it when it is there, so that the incidence of this complication in any clinical series of patients depends mostly on the depth of the physician's interest in this subject and on his awareness of, or 320' Section of Medicine indifference to, its occurrence, and not on the efficacy of any remedy given to prevent it. This explains why a statistical analysis of the incidence of this complication from special therapeutic measures has remained, and is destined to remain, confused. LABORATORY CONTROL OF ANTICOAGULANT THERAPY It is next necessary to consider the difficulty of controlling the dosage of this drug in individual patients based on estimates made in the laboratory. The coagulant property of the blood is determined in different ways; the simplest of them is not an easy procedure. Little wonder, therefore, that the results vary from laboratory to laboratory. Again, although the estimation of the prothrombin time is now the customary test the heparin tolerance test may have to be added. When these two tests were carried out by Beaumont et al. (1953) they found three separate phases during the course of cardiac infarction. The first phase, limited to the first two days of the illness, showed the blood to be in a state of extreme hypercoagulability. The second phase, lasting a week or so, showed hypocoagulability. This was followed by a phase of hypercoagulability variable in its degree and duration, but often lasting for a long time. Three practical lessons are drawn from these observations. First, those pledged to this form of treatment have neglected their patient if therapy is not commenced during the first few hours of the illness, seeing that the state of hypercoagulability is most obvious on the first day. This involves starting the treatment in the patient's home and demanding hospital accommodation within forty-eight hours. Such an arrangement is impracticable in the large majority of cases. Secondly, the observations point not only to the needlessness of anticoagulant therapy in the subsequent week, but also to the danger of prescribing it at such a time lest it incurs bleeding into the necrotic tissue of the infarcted area or elsewhere. Thirdly, the observations emphasize the return of a state of hypercoagulability after the tenth day of the illness, and this may last for days or even months. If it is the design of anticoagulants to prevent cardiac thrombosis it should be given in perpetuity because the threat of a recurrence or extension of the trouble remains. How inconsistent, therefore, is the doctor who prescribes anticoagulants to his patient for a time only, how unscientific are his tactics, and how certain it is that the future will condemn them. Furthermore, coagulability of the blood determined in the laboratory is not an infallible index of blood clotting in the patient. Thus, a number of examples may be met where the prothrombin time is not unduly low and yet the patient bleeds and again where the test told of hypocoagulability while thrombo-embolic incidents were recurring. Such facts supply proof once more that reactions in a test tube in the laboratory differ materially from those shown by the patient in his bed. To the difficulty of assessing the efficiency of anticoagulants because of the impossibility of assembling a strictly' comparable series of patients to control the clinical results, is added, therefore, the difficulty of controlling the dosage of anticoagulants in the laboratory.
HAEMORRHAGE DuRING ANTICOAGULANT THERAPY Bleeding is the only unfavourable symptom arising directly from anticoagulant drugs and it has been seen that laboratory tests cannot obviate the risk. It has been said that deaths from thromboembolism can be abolished by Tromexan, but is death from haemorrhage, which is then to become the greater risk, to be favoured on account of a more tranquil end? The place of the bleeding matters .321
Proceedings of the Royal Sociy of Medicine 12 as much as its extent; it may be of no consequence if it happens in the nose or the skin, but it is of great moment if it originates in an ulcerated stomach or intestine, in the internal capsule of the brain, in the pericardium, or in the necrotic infarcted area of the heart thereby exaggerating the injury it is meant to heal. Looking over other doctors' shoulders I have witnessed all these fatal complications taking place. Many advocates of anticoagulant therapy fail to mention the risks attendant on it, others allude casually to the occurrence of hemorrhage in some of their patients, while others conveniently attribute the fatal mishap to a hremorrhagic diathesis (Duff and Shull, 1949) . One investigation (Editorial, J. Amer. med. Ass., 1950) concerned with 15,500 patients treated with anticoagulants found that severe himorrhage happened in 2% of the cases. Wright and his associates (1948) reported haemorrhage in 9 % of their patients and in an additional 6 % where the bleeding was not considered to have been caused by the anticoagulant remarkable also was the finding of bleeding in 6 % in the control group. Russek and Zohman (1953) reported on the questionnaire sent to leading cardiologists in the United States; serious hvmorrhagic complications were encountered by 104 or 45% of the 228 physicians in this survey, and a total of 122 deaths caused by bleeding, mostly into the brain, gastro-intestinal tract or pericardium, was met with.
Vitamin K can do little to counteract thiese serious episodes for irretrievable damage has been the signal for the need to use it. In this context it is rather ironical that proprietary establishments which supply a particular anticoagulant also provide their own brand of vitamin K so that Tromexan begets Synkayvite and Cumopyran its Hykinone. It causes us to think when the sale of a particular poison might be urged to boost the good offices of its corresponding antidote. CONCLUSIONS It is wisdom. never to accept hastily the claims of newer remedies; it is duty to reject resolutelv their use if they have failed after trial to reach an agreed standard of efficiency. Anticoagulant therapy has failed to satisfy any of the three demands made by the code set to test its efficiency in coronary-occlusion.
It is purposeless to apply such treatment in more than one-half the patients with cardiac infarction with a view to preventing the extension of coronary thrombosis in that thrombosis is not taking place in them.
A comparison of the mortality rate in patients receiving anticoagulants with that in cases receiving orthodox treatment provides no justification for the continued use of this therapy in any kind of coronary arterial disease.
Again, a comparison of the incidence of thrombo-embolism in the test and control groups gives no support to the recommendation that anticoagulants should be dispensed to patients with coronary occlusion with .the object of avoiding this complication.
Furthermore, severe hamorrhage even under close laboratory supervision, and ungovemable by vitamin K if it is taking place in vital tissues, is frequent enough to condemn the use of anticoagulants in coronary occlusion.
Lastly, it is a sound precept in medicine never to dispense a remedy to a patient when there is doubt that it can do good and when it is known that it can do harm. That anticoagulant treatment in coronary occlusion will go the way of other discarded remedies is certain. Let it go soon. Let it go now, before remorse weighs too heavily on those who may continue for a little time longer to advocate its use.
